X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is...
5 insider purchases on record · latest filing 2025-10-27.
Insiders have also filed 84 sale transactions at XFOR.